Skip to main content

Table 3 Sensitivity, specificity, PPV and NPV of serum S100B and PET-CT for patients with stage I or II

From: Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

Pts with stage I or II

(68)

 

PPV %

(N)

NPV%

(N)

Sensitivity% (N)

Specificity% (N)

S100B

80.0% (28/35)

21.2% (7/33)

51.8% (28/54)

50.0% (7/14)

PET-CT

98.2% (54/55)

100.0% (13/13)

100.0% (54/54)

92.8% (13/14)

With clin. sign

(48)

 

PPV%

(N)

NPV%

(N)

Sensitivity% (N)

Specificity% (N)

S100B

93.3 (14/15)

21.3 (7/33)

65.0 (26/40)

87.5 (7/8)

PET-CT

97.5 (40/41)

100.0 (7/7)

100.0 (40/40)

87.5 (7/8)

Asymptomatic pts

(20)

 

PPV%

(N)

NPV%

(N)

Sensitivity% (N)

Specificity% (N)

S100B

70.0 (14/20)

0 bias

100.0 (14/14)

0 bias

PET-CT

100.0 (14/14)

100.0 (6/6)

100.0 (14/14)

100.0 (6/6)